To Study the Function of the Retina in Glaucoma Patients Using PERG

A Prospective, Longitudinal Study to Evaluate the Function of the Retina and Visual Pathways in Glaucoma Patients Using PERG

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03330574

Enrollment

200

Registered

2017-11-06

Start date

2017-01-01

Completion date

2023-12-31

Last updated

2022-05-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Glaucoma

Keywords

Glaucoma

Brief summary

The purpose of this trial is to evaluate the performance of a new diagnostic device in the diagnosis and management of glaucoma. We will use this new device (PERG) to evaluate the function of the retina in glaucoma patients. This device is safe for the patients.

Detailed description

Glaucoma is one of the leading causes of blindness worldwide. It's an optic neuropathy characterized by the progressive death of retinal ganglion cells. In laboratories, it's possible to measure the electrical activity of retinal ganglion cells (RGC). Some researchers found that RGC showed electrical anomalies before dying. This decrease of electrical activity can be measured by using pattern electroretinography (PERG). Unfortunately, these measures could not be obtained in clinics before this new device. For this reason, Diopsys developed a new device that can measure PERG directly in clinics, allowing physicians to have these data earlier to help them diagnose pathologies such as glaucoma or other ganglion cells abnormalities. Currently, it is known that glaucoma is difficult to diagnose in the early stages and it's challenging to decide when to start a treatment. In this study, our purpose is to use this new device to evaluate its efficacy in the diagnosis and management of glaucoma.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* Glaucoma (all types of glaucoma); * Ocular hypertensive (Suspicion of glaucoma); * Control Patients (without any suspicion/sign of glaucoma); * Have given written informed consent, prior to any investigational procedures; * Aged 18 years of either sex.

Exclusion criteria

* Patients not able to understand the character of the study * Participation in other clinical research within the last 4 weeks * Other diseases that may cause visual field loss or optic disc abnormalities * Systemic diseases that may affect PERG amplitude such as diabetes, parkinsonism, multiple sclerosis * Poor best corrected visual acuity outside the limits recommended for the test * Patients with high myopia (\>5D)

Design outcomes

Primary

Measure	Time frame	Description
Magnitude, μV	4 years	Strength of the signal
Magnitude D, μV	4 years	Strength and phase
MagD/Mag Ratio (no units)	4 years	Ratio between MagD and Mag
SNR, dB	4 years	Signal to Noise Ratio

Countries

Switzerland

Outcome results